Evidence-based access to the full market
One sponsor-neutral channel with clinical intelligence built in. See everything, compare objectively, prescribe with confidence.
What clinical access means
Tools and intelligence designed for evidence-based prescribing, not sales-driven recommendations.
Full Market Visibility
Every product available in Australia, across all sponsors, in one searchable interface. Real-time stock, pricing, and availability.
COMPASS Clinical Comparison
Compare products side-by-side by cannabinoid profile, terpene content, dose form, and clinical evidence. Make decisions based on data, not marketing.
Terpene & Chemovar Intelligence
Deep product intelligence including full terpene profiles, chemovar classifications, and indica/sativa ratios to support precision prescribing.
Aggregated Outcome Data
De-identified, aggregated outcome data from across the network to inform prescribing decisions and identify what works for specific conditions.
Smart Substitution Engine
When a product is unavailable, instantly find clinically equivalent alternatives ranked by similarity to the original prescription.
How it differs
Traditional distributor
- Limited to their sponsor portfolio
- Product recommendations driven by margin
- No clinical data or comparison tools
- Prescriber treated as a sales target
CWA Clinical Access
- Full market across all sponsors
- Recommendations driven by clinical evidence
- COMPASS, terpene data, outcome tracking
- Prescriber treated as a clinical partner